SCHEMBL4879515

SCHEMBL4879515

O=C(Nc1csc(-c2ccc(F)cc2F)n1)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.43
MAPT P10636 5/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 4/20 0.41
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
EIF4E P06730 2/20 0.39
HDAC4 P56524 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542428 0.72 LDHA (0.57) RAB9ALMNAALDH1A1SMN1; SMN2EIF4E
Hydrochloric Acid SCHEMBL6818629 0.71 LDHA (0.56) RAB9ALMNAALDH1A1SMN1; SMN2EIF4E
SCHEMBL6818626 0.71 LMNA (0.51) MAPTRAB9ANPC1LMNAALDH1A1
SCHEMBL11490856 0.70 CA2 (0.40) ABL1RAB9ANPC1SMN1; SMN2HDAC4
SCHEMBL2554722 0.70 NPSR1 (0.57) MAPTRAB9ANPC1LMNAALDH1A1
SCHEMBL4868714 0.70 MPL (0.74) MPL
SCHEMBL4868717 0.69 MAPT (0.39) MAPTRAB9ANPC1LMNAALDH1A1
SCHEMBL21861332 0.69 TRPA1 (0.40) MAPTRAB9ANPC1ALDH1A1
SCHEMBL31548138 0.69 HTT (0.57) MAPTRAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL9359721 0.69 HTT (0.57) MAPTRAB9ANPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076771-A1 Thrombopoietin Receptor Agonists REITER LAWRENCE A 2008-03-27 US disclosed
EP-1794156-A2 TROMBOPOIETIN RECEPTOR AGONISTS Pfizer Products Incorporated (US) 2007-06-13 EP disclosed
WO-2006033005-A2 THROMBOPOIETIN RECEPTOR AGONISTS PFIZER PRODUCTS INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076771-A1 Thrombopoietin Receptor Agonists MPL, THPO, TBXA2R ABL1 603/4885MAPT 4880/4885RAB9A 2219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.